Skip to main content
INVENTISBIO CO., LIMITED. logo

INVENTISBIO CO., LIMITED. — Investor Relations & Filings

Ticker · 688382 ISIN · CNE100005Q22 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 445 across all filing types
Latest filing 2026-02-10 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688382

About INVENTISBIO CO., LIMITED.

https://www.inventisbio.com/

InventisBio Co., Ltd. is a clinical-stage biopharmaceutical company dedicated to the discovery and development of innovative small molecule therapeutics. The company focuses on addressing unmet medical needs in oncology and metabolic diseases. Its research and development pipeline includes several high-potential candidates, such as befotertinib, a third-generation EGFR tyrosine kinase inhibitor for non-small cell lung cancer, and garsorasib, a potent KRAS G12C inhibitor. Additionally, the company is developing D-0502, an oral selective estrogen receptor degrader for breast cancer, and D-0120, a selective URAT1 inhibitor for the treatment of hyperuricemia and gout. InventisBio leverages its proprietary drug discovery platform and global clinical development expertise to advance a diverse portfolio of targeted therapies aimed at improving patient outcomes through precision medicine.

Recent filings

Filing Released Lang Actions
益方生物第二届董事会2026年第一次会议决议公告
Board/Management Information Classification · 95% confidence The document is an announcement of resolutions passed at the company's board of directors meeting, including approval of investment project adjustments, establishment of a market value management system, and senior management performance evaluation. It includes details about the meeting date, attendance, and voting results. There is no financial data or detailed report content, but rather a formal disclosure of board decisions. This fits the category of Board/Management Information (MANG), which covers announcements of changes or decisions by the board or senior management.
2026-02-10 Chinese
君合律师事务所关于益方生物科技（上海）股份有限公司2025年限制性股票激励计划（草案）的法律意见书
Regulatory Filings Classification · 82% confidence The document is a law firm’s legal opinion (法律意见书) on the company’s proposed 2025 restricted stock incentive plan (draft). It contains legal analysis and certifications under Chinese corporate and securities laws, but no financial statements or quantitative results. It serves as a compliance/legal attestation filed with regulators (Shanghai Stock Exchange) rather than being an actual annual or interim report, earnings release, or investor presentation. Under the Certification Rule and fallback for miscellaneous regulatory compliance documents, this should be classified as a Regulatory Filing (RNS).
2026-02-10 Chinese
益方生物2025年年度业绩预亏公告
Earnings Release Classification · 95% confidence The document is an announcement of the company's expected annual performance loss for the fiscal year 2025, including preliminary profit and revenue estimates, reasons for performance changes, and risk warnings. It explicitly states that the financial data is preliminary, unaudited, and that the final audited data will be disclosed in the formal 2025 annual report. The document length is short (1573 characters) and it serves as a performance forecast rather than a full financial report. Therefore, it is an Earnings Release (ER) type document, which typically includes initial quarterly or annual financial results highlights and forecasts. FY 2025
2026-01-29 Chinese
益方生物首次公开发行部分限售股上市流通公告
Regulatory Filings Classification · 95% confidence The document is an official announcement regarding the listing and circulation of restricted shares from the company's initial public offering (IPO). It details the number of shares becoming tradable, the lock-up periods, shareholder commitments, and regulatory compliance confirmations. It references the approval from the China Securities Regulatory Commission and the Shanghai Stock Exchange listing rules. The document does not contain financial statements or performance data but focuses on the share listing event and related shareholder commitments. This fits the category of a Regulatory Filing (RNS) as it is a formal regulatory announcement about share circulation and compliance, not a financial report or earnings release.
2026-01-16 Chinese
中信证券股份有限公司关于益方生物科技（上海）股份有限公司首次公开发行部分限售股上市流通的核查意见
Regulatory Filings Classification · 85% confidence The document is a sponsor’s verification opinion (“核查意见”) regarding the lifting of lock-up restrictions and listing of restricted shares following an IPO. It contains legal and regulatory compliance statements, detailed shareholding schedules, and commitments by controlling shareholders. It is not an annual or interim report, earnings release, dividend notice, or management/call transcript. It is a specific regulatory disclosure submitted to the exchange that does not fit other precise categories, so it falls under Regulatory Filings (RNS).
2026-01-16 Chinese
益方生物董事会薪酬与考核委员会关于公司2025年限制性股票激励计划激励对象名单的审核意见及公示情况说明
Remuneration Information Classification · 95% confidence The document is an announcement from the board's remuneration and assessment committee regarding the review and public disclosure of the list of incentive recipients under the company's 2025 restricted stock incentive plan. It details the board meeting resolutions, public notice, and verification of eligibility of the incentive recipients according to relevant laws and regulations. The content focuses on remuneration and incentive plan details rather than full financial results, audit, or governance structure changes. It is not a full report but an announcement related to executive compensation and stock incentive plans. Therefore, it fits best under Remuneration Information (DEF 14A), which covers reports detailing compensation and incentive plans for executives and directors.
2026-01-07 Chinese

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.